Should I buy Harmony Biosciences Holdings, Inc. (HRMY) stock or is it too late?
⭐ The most reliable of them, either direction: HC Wainwright & Co. — 61% of its targets hit on this sector (321 calls tested). It aims for $55 (+38 %), call made on July 17, 2026, maturing on July 17, 2027 (42 d ago).
Firm-by-firm track record on Harmony Biosciences Holdings, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| HC Wainwright & Co. | 33 % | -3.9 % | 6 | $55 +38% |
| Oppenheimer | 17 % | -4.7 % | 6 | $61 +53% |
| Needham | 43 % | -5.7 % | 37 | $50 +25% |
| Cantor Fitzgerald | 50 % | -7.4 % | 8 | $58 +45% |
| Mizuho | 38 % | -13.6 % | 16 | $51 +28% |
| Raymond James | 67 % | +4.0 % | 6 | — |
✅ Reasons to believe
- 60% of analysts rate it a buy (Buy consensus, 5 ratings) — a sign of market conviction.
- Median price target $50, i.e. +25% from the current price ($40).
⚠️ Reasons to hesitate
- Even the most reliable firm on HRMY, Deutsche Bank (50% hit rate, 2 scored calls), only targets $36 (call made on June 30, 2026, maturing on June 30, 2027) (-10%) in its most recent call, and $36 (call made on September 25, 2025, maturing on September 25, 2026) (-10%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 5 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on HRMY
Median target $50 (+25%) · 5 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Harmony Biosciences Holdings, Inc. now?
We won't decide for you. The facts: 60% of analysts rate it a buy, median target $50 (+25%), and Deutsche Bank (most reliable on HRMY, 50%) targets $36. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Harmony Biosciences Holdings, Inc.?
Not according to analysts: the median target ($50) is still +25% above the current price ($40) (most reliable on HRMY: Deutsche Bank, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Harmony Biosciences Holdings, Inc. still worth investing in?
It depends on the gap between the price ($40) and its estimated value: analysts target $50 on median (+25%), with 60% buys (most reliable on HRMY: Deutsche Bank, 50%). Cross-check with their real reliability on HRMY and the cautions above. Information, not advice.
What's the main risk in buying HRMY?
Even the most reliable firm on HRMY, Deutsche Bank (50% hit rate, 2 scored calls), only targets $36 (call made on June 30, 2026, maturing on June 30, 2027) (-10%) in its most recent call, and $36 (call made on September 25, 2025, maturing on September 25, 2026) (-10%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Harmony Biosciences Holdings, Inc. profile (consensus, analyst reliability, price target, performance).